Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) EVP Matthias Alder sold 150,000 shares of the stock in a transaction on Monday, November 28th. The stock was sold at an average price of $16.00, for a total value of $2,400,000.00. Following the completion of the sale, the executive vice president now owns 29,449 shares in the company, valued at approximately $471,184. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) opened at 16.25 on Thursday. The stock’s 50 day moving average price is $13.49 and its 200-day moving average price is $12.15. Sucampo Pharmaceuticals Inc. has a 52 week low of $9.59 and a 52 week high of $18.75. The company has a market capitalization of $695.79 million, a PE ratio of 54.90 and a beta of 1.62.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The firm earned $57.90 million during the quarter, compared to the consensus estimate of $51.30 million. During the same quarter in the previous year, the firm posted $0.16 EPS. The company’s revenue for the quarter was up 73.4% compared to the same quarter last year. On average, equities research analysts predict that Sucampo Pharmaceuticals Inc. will post $1.22 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Financial Market News and is the propert of of Financial Market News. If you are reading this piece on another site, it was illegally stolen and republished in violation of United States and international copyright law. The original version of this piece can be read at http://www.financial-market-news.com/matthias-alder-sells-150000-shares-of-sucampo-pharmaceuticals-inc-scmp-stock/1211949/.

A number of equities research analysts recently issued reports on the company. Maxim Group increased their price objective on Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, November 15th. Mizuho increased their price objective on Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, November 14th. Jefferies Group reiterated a “hold” rating and issued a $16.00 price objective (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Friday, November 11th. Vetr downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price objective on the stock. in a research report on Monday, September 19th. Finally, Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Sucampo Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $17.33.

Several large investors have recently modified their holdings of the stock. LSV Asset Management increased its stake in shares of Sucampo Pharmaceuticals by 258.7% in the third quarter. LSV Asset Management now owns 1,730,916 shares of the biopharmaceutical company’s stock worth $21,307,000 after buying an additional 1,248,389 shares during the last quarter. Royce & Associates LP increased its stake in shares of Sucampo Pharmaceuticals by 2,005.0% in the second quarter. Royce & Associates LP now owns 367,516 shares of the biopharmaceutical company’s stock worth $4,032,000 after buying an additional 350,057 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its stake in shares of Sucampo Pharmaceuticals by 227.3% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 367,900 shares of the biopharmaceutical company’s stock worth $4,036,000 after buying an additional 255,500 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Sucampo Pharmaceuticals by 3,990.7% in the second quarter. Stonepine Capital Management LLC now owns 213,860 shares of the biopharmaceutical company’s stock valued at $2,346,000 after buying an additional 208,632 shares in the last quarter. Finally, TFS Capital LLC increased its position in shares of Sucampo Pharmaceuticals by 1,293.3% in the second quarter. TFS Capital LLC now owns 160,695 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 149,162 shares in the last quarter. 41.12% of the stock is owned by hedge funds and other institutional investors.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.